Celsius42
Celsius42 GmbH, a private German medical-technology company, develops and sells the Celsius TCS — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used by hospitals and oncology centers as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment.
- Company typePrivate
- Founded2006
- HeadquartersEschweiler, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Celsius42 does
Celsius42 GmbH is a privately-held German medical-technology company headquartered in Eschweiler that develops, manufactures, and distributes the Celsius TCS (Tumor Cell Solution) — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment. The system differentiates through a dual active electrode architecture with variable electrode sizes, automatic electrode recognition, hydraulic patient positioning, high-capacity water cooling for deep tissue penetration, programmable treatment protocols, and a Linux-based operating system for data security. It is indicated for a broad range of solid tumors across gynecological, organ-based (brain, liver, lung, kidney, pancreas, esophagus), gastrointestinal, sarcoma, and melanoma indications in both curative and palliative settings.
The company operates an enterprise field-sales model targeting hospitals with radiotherapy departments and oncology outpatient centers, combining direct sales, mandatory maintenance agreements (required under the German Medical Device Act), and downstream per-treatment-session economics (German GOÄ billing at €145.14 per session accrues to providers). International reach is delivered through a wholly-owned Korean subsidiary (Celsius42 Korea LTD in Gunpo) serving Asia and a strategic long-term alliance with Dubai-based Lootah Group covering the Middle East, Africa, and India, with a planned Dubai office. Named clinical reference sites include Charité University Hospital Berlin, Clinic St. Georg Bad Aibling, and the KSA-KSB Cancer Center Aarau in Switzerland.
Celsius42 was founded in 2006, underwent insolvency-driven restructuring of its legacy Celsius42+ GmbH entity in 2016 due to new medical-device regulatory requirements, and re-emerged under new leadership in 2017-2018 with Christian Hartmann as CEO. The company relocated to larger facilities in Eschweiler in February 2019 (incorporating a training academy), achieved its best half-year financial result ever in H1 2020 despite COVID-19 disruption, and reported 1-10 employees on standard business profiles. No external institutional funding, venture capital, or public market activity is disclosed.
Celsius42 firmographics
Firmographics- Name
- Celsius42
- Legal name
- Celsius42 GmbH
- Website
- https://celsius42.de
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Celsius42 GmbH, a private German medical-technology company, develops and sells the Celsius TCS — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used by hospitals and oncology centers as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment.
- Ownership category
- akta.pro rank
Celsius42 industry classification
Industry- Product category
- Oncology Hyperthermia Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where Celsius42 is headquartered
LocationHeadquarters
- HQ city
- Eschweiler
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
Celsius42 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel
Revenue model
- Medical Device Sales (Celsius TCS Hyperthermia System): Sale of the Celsius TCS hyperthermia medical device to hospitals and oncology centers. The system includes hardware components and requires mandatory maintenance agreements.
- Mandatory Maintenance Agreements: Due to the complex nature of the medical device under the Medical Device Act (Medizinproduktgesetz), mandatory maintenance is required during the warranty period. Maintenance agreements are obligatory upon acquisition and include support services, telephone hotline, and proactive maintenance.
- Per-Treatment Session Billing: Regional deep hyperthermia treatments are typically billed according to the German medical fee schedule (GOÄ) at 145.14 Euro per treatment session (GOÄ number 5854). Revenue accrues per treatment delivered to patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Per treatment session: 145.14 Euro (GOÄ 5854) |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Celsius42 product offering
Product offeringCore offering
Celsius42 develops, manufactures, and sells the Celsius TCS (Tumor Cell Solution), a 13.56 MHz radiofrequency capacitive hyperthermia medical device for regional deep hyperthermia cancer treatment. The system is sold to hospitals and oncology outpatient centers as a complementary therapy to enhance the effectiveness of radiotherapy and chemotherapy for solid tumors, with mandatory maintenance agreements and per-treatment session billing.
Product overview
Celsius42 offers a single unified medical device product: the Celsius TCS (Tumor Cell Solution) hyperthermia system. This is a capacitive regional deep hyperthermia medical device designed as a complementary cancer therapy to enhance the effectiveness of radiation and chemotherapy. The system operates at a carrier frequency of 13.56 MHz and features dual active electrodes with intelligent recognition, hydraulic positioning arms, programmable treatment protocols, and sustainable water cooling for effective deep-tissue heating. The product is supported by workflow management software, patient databases, and medical documentation features, all running on a Linux-based operating system.
Differentiator
Problem solved
Functional benefit
Brands
- Celsius TCS – Tumor Cell Solution: The TCS (Tumor Cell Solution) hyperthermia system for regional deep hyperthermia treatment, using 13.56 MHz RF frequency technology to heat tumor tissue as an adjunct to radiotherapy and chemotherapy.
Products and services
- Celsius TCS (Tumor Cell Solution) A 13.56 MHz capacitive radiofrequency regional deep hyperthermia medical device for cancer treatment, sold to hospitals with radiotherapy departments and oncology outpatient centers. Features dual active electrodes, variable electrode sizes, high-capacity water cooling, automatic electrode recognition, patient safety monitoring, and individually programmable treatment protocols on a Linux-based platform. Indicated for solid tumors including gynecological malignancies, organ tumors, deep-seated lesions, lymph node metastases, gastrointestinal tumors, sarcomas, and melanomas, used as an adjunct to radiotherapy and chemotherapy.
Quantifiable outcome
- Radiotherapy effectiveness increased by factor of 1.2 to 5 when combined with hyperthermia
- +2 more outcomes
Companies that use Celsius42
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Celsius42 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Celsius42 partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Lootah GroupcoreLong-term and extensive strategic cooperation between Celsius42 and Dubai-based Lootah Group to expand hyperthermia cancer treatment in Middle East, Africa, and India. Lootah Group, led by Ibrahim Saeed Lootah, is recognized as a pioneer in broad-based core technologies with 37+ manufacturing facilities and owns a medical university in Dubai. Partnership aims to establish hyperthermia as essential component of medical education and build dedicated cancer treatment centers.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Celsius42 competitors and assessment
Company assessmentDirect peers
- MagForce AG: Frankfurt-listed German company using magnetic nanoparticle-based thermotherapy (NanoTherm) for glioblastoma and prostate cancer; alternative technology approach in the same oncology-hyperthermia category.
- Pyrexar Medical: US-based manufacturer of regional and superficial hyperthermia systems (BSD-500, BSD-2000). Direct competitor to Celsius42's TCS in the same capacitive RF deep hyperthermia category for oncology.
- Oncotherm: Hungarian/German manufacturer of regional deep hyperthermia devices (EHY series) using capacitive RF at 13.56 MHz — the closest technology and market overlap with Celsius TCS.
- Dr. Sennewald Medizintechnik GmbH: German specialty manufacturer of hyperthermia systems for oncology; competes head-to-head with Celsius42 in the DACH radiotherapy clinic segment.
Broad incumbents
- Elekta: Swedish radiation oncology and radiosurgery vendor (Versa HD, Elekta Infinity, Leksell Gamma Knife). Competes for radiotherapy department capital budgets that Celsius42 depends on for placement.
- Accuray: Maker of CyberKnife and TomoTherapy radiation therapy systems; broad incumbent in radiation oncology whose customer sites are the natural channel for Celsius42's adjunct hyperthermia.
- Varian Medical Systems (Siemens Healthineers): Global leader in linear accelerators and radiotherapy software (TrueBeam, Ethos, ARIA). A broad incumbent whose installed base defines where hyperthermia adjuncts like Celsius TCS are sold.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Celsius42 social profiles
Digital presenceCelsius42 financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celsius42 leadership team
Management profileNumber of profiles
Profiles2 records
Celsius42 subsidiaries and ownership
Company hierarchySubsidiaries2 records
Celsius42 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celsius42 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celsius42
What does Celsius42 do?
Celsius42 develops, manufactures, and sells the Celsius TCS (Tumor Cell Solution), a 13.56 MHz radiofrequency capacitive hyperthermia medical device for regional deep hyperthermia cancer treatment. The system is sold to hospitals and oncology outpatient centers as a complementary therapy to enhance the effectiveness of radiotherapy and chemotherapy for solid tumors, with mandatory maintenance agreements and per-treatment session billing.
Is Celsius42 a public or private company?
Celsius42 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Celsius42 founded?
Celsius42 was founded in 2006. It employs 1 to 10 people.
Where is Celsius42 based?
Celsius42 is headquartered in Eschweiler, Germany, in the Europe region.
How does Celsius42 make money?
Three revenue lines are on record. Medical Device Sales (Celsius TCS Hyperthermia System) is the primary driver. The others are mandatory Maintenance Agreements and per-Treatment Session Billing.
Who are Celsius42's main competitors?
Direct peers on record are MagForce AG, Pyrexar Medical, Oncotherm and Dr. Sennewald Medizintechnik GmbH. Broad incumbents are Elekta, Accuray and Varian Medical Systems (Siemens Healthineers).
Does Celsius42 have an API?
No public API is recorded for Celsius42.
What industry is Celsius42 in?
Celsius42's product category is Oncology Hyperthermia Medical Devices. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology. Its NAICS code is 334510 and its SIC code is 3845.